Satellos Bioscience Inc. Completes Share Rollback and Announces New Chief Development Officer
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a clinical‑stage biotechnology company focused on skeletal muscle regeneration, completed a 1:12 share rollback on January 28, 2026. The transaction reduced the number of outstanding shares, aligning the company’s share structure with its planned Nasdaq listing and improving liquidity for investors.
Share Consolidation
- Date of completion: January 28, 2026
- Nature of the transaction: 1:12 share rollback (also described as a share consolidation)
- Purpose: To prepare for an upcoming Nasdaq listing, thereby increasing the company’s visibility and access to a broader investor base.
The share consolidation was reported by multiple outlets, including StockWatch, Marketscreener, and InvestingNews. All reports confirm the completion of the rollback and highlight the company’s strategic intent to list on Nasdaq.
Leadership Update
On January 29, 2026, Satellos announced the appointment of Antoinette Paone as Chief Development Officer (CDO). The appointment was reported in both English and German sources (Investing.com and de.investing.com). Paone will oversee the company’s development pipeline, which aims to develop medicines that restore the body’s innate capacity for muscle self‑repair.
Company Context
- Sector: Health Care
- Industry: Biotechnology
- Primary Exchange: Toronto Stock Exchange (TSX Venture)
- Market Capitalisation: 248 579 584 CAD
- Price‑to‑Earnings Ratio: –6.24 (negative, indicating losses)
- Stock Performance (as of 2026‑01‑27): Close price 1.22 CAD; 52‑week high 1.37 CAD; 52‑week low 0.52 CAD.
Satellos’s mission is to develop therapies for degenerative muscle diseases, positioning itself as a potential leader in skeletal muscle regeneration.
